CDC’s COVID-19 vaccine safety group reviews ‘few’ reports of myocarditis in young people
The CDC’s COVID-19 vaccine safety group recently reviewed what it said were “relatively few reports” of myocarditis among young recipients of the messenger RNA-based COVID-19 vaccines.
According to an update posted on the web page of the Advisory Committee on Immunization Practices’ COVID-19 Vaccine Safety Technical (VaST) Work Group, the group’s May 17 meeting included several presentations on the risk for myocarditis following the administration of one of the mRNA COVID-19 vaccines.
“VaST concluded that there are relatively few reports of myocarditis to date,” the update reads.
According to the group, the cases seem to occur:
- predominantly in adolescents and young adults;
- more often in males than in females;
- more often following the second dose than the first; and
- typically, within 4 days after vaccination.
“Most cases appear to be mild, and follow-up of cases is ongoing,” the group said.
Details of the meeting were first reported by The New York Times.
According to the update, rates of myocarditis following the administration of one of the mRNA vaccines are not different from expected baseline rates. “However, VaST members felt that information about reports of myocarditis should be communicated to providers.”
“Collaboration between infectious diseases, cardiology, and rheumatology specialists is needed to provide guidance on diagnosis, treatment, and management of myocarditis,” the group said.
The available mRNA vaccines in the United States are made by Pfizer-BioNTech and Moderna. The Pfizer-BioNTech vaccine is available for anyone aged 12 years or older, and the Moderna vaccine is available for adults aged 18 years or older.